[Clinical experiences with Ro 6-2580 in dermatology].
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011511:Proteus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011743:Pyrimidines / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013420:Sulfamethoxazole
Klinische Erfahrungen mit Ro 6-2580 in der Dermatologie.